At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 143 enrolled
Drug / intervention
Eucerin +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial
In Brief
A Phase 3 clinical trial evaluating Eucerin and Mometasone Furoate 0.1% for Invasive Breast Cancer. Completed, enrolled 143 participants across 6 sites.
Detailed Summary
The purpose of this study is to find out if the effect of mometasone furoate is any different from Eucerin in decreasing the severity of redness of the skin during irradiation, preventing the skin from peeling, or reducing the amount of irritation the patient reports during treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionJan 2017
TodayJul 2026
First PostedMay 17, 2013
Enrollment StartMay 1, 2013
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 13.1 years ago
Interventions
Eucerinother
Mometasone Furoate 0.1%other